Literature DB >> 15516669

Prevalence and rate of diagnosis of allergic rhinitis in Europe.

V Bauchau1, S R Durham.   

Abstract

To measure the prevalence of allergic rhinitis among European adults and the proportion of undiagnosed subjects, a two-step, cross-sectional, population-based survey in Belgium, France, Germany, Italy, Spain, and the UK was undertaken. Step one of the study involved screening for allergic rhinitis by telephone interview, based on history of symptoms and/or self-awareness of the condition. Step two undertook confirmation of allergic rhinitis in a subset of the subjects screened positive; this was performed by a clinical diagnosis conducted in three to five clinical centres per country, including specific immunoglobulin E tests and a disease-specific questionnaire. A total of 9,646 telephone interviews were conducted between February and April 2001. Self-awareness of allergic rhinitis was reported by 19% of the subjects. Physician-based diagnosis of allergic rhinitis was reported by 13% of the subjects. In step two, 725 clinical assessments were conducted between May and August 2001. A total of 411 of patients, who underwent step two, had investigator-confirmed allergic rhinitis. Among patients with investigator-confirmed allergic rhinitis, 45% had not reported a previous diagnosis by a physician. Prevalence of subjects with clinically confirmable allergic rhinitis estimated by combining step one and step two data ranged from 17% in Italy to 29% in Belgium with an overall value of 23%. This large-scale study confirms that allergic rhinitis has a high prevalence in western Europe and is frequently undiagnosed.

Entities:  

Mesh:

Year:  2004        PMID: 15516669     DOI: 10.1183/09031936.04.00013904

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  213 in total

1.  Examining the utilization and tolerability of the non-sedating antihistamine levocetirizine in England using prescription-event monitoring data.

Authors:  Deborah Layton; Vicki Osborne; Anna Gilchrist; Saad A W Shakir
Journal:  Drug Saf       Date:  2011-12-01       Impact factor: 5.606

2.  [Rhinosinusitis guidelines--unabridged version: S2 guidelines from the German Society of Otorhinolaryngology, Head and Neck Surgery].

Authors:  B A Stuck; C Bachert; P Federspil; W Hosemann; L Klimek; R Mösges; O Pfaar; C Rudack; H Sitter; M Wagenmann; R Weber; K Hörmann
Journal:  HNO       Date:  2012-02       Impact factor: 1.284

3.  Interactions of physical, chemical, and biological weather calling for an integrated approach to assessment, forecasting, and communication of air quality.

Authors:  Thomas Klein; Jaakko Kukkonen; Aslög Dahl; Elissavet Bossioli; Alexander Baklanov; Aasmund Fahre Vik; Paul Agnew; Kostas D Karatzas; Mikhail Sofiev
Journal:  Ambio       Date:  2012-05-25       Impact factor: 5.129

4.  Clinical course of rhinitis and changes in vivo and in vitro of allergic parameters in elderly patients: a long-term follow-up study.

Authors:  Gabriele Di Lorenzo; Maria Stefania Leto-Barone; Simona La Piana; Vito Ditta; Gaetana Di Fede; Giovam Battista Rini
Journal:  Clin Exp Med       Date:  2012-02-04       Impact factor: 3.984

Review 5.  Concomitant corticosteroid nasal spray plus antihistamine (oral or local spray) for the symptomatic management of allergic rhinitis.

Authors:  Shaoyan Feng; Yunping Fan; Zibin Liang; Renqiang Ma; Wanwei Cao
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-11-06       Impact factor: 2.503

Review 6.  Phenotyping of allergic rhinitis.

Authors:  Cemal Cingi; Tolgahan Catli
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

7.  Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX®) in a real-life setting for three consecutive seasons - the GRAAL trial.

Authors:  François Wessel; Antoine Chartier; Jean-Pierre Meunier; Antoine Magnan
Journal:  Clin Drug Investig       Date:  2012-07-01       Impact factor: 2.859

8.  Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England.

Authors:  Deborah Layton; Lynda Wilton; Saad A W Shakir
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 9.  New routes for allergen immunotherapy.

Authors:  Pål Johansen; Seraina von Moos; Deepa Mohanan; Thomas M Kündig; Gabriela Senti
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 10.  Comparative analysis of allergic rhinitis in children and adults.

Authors:  Adriana Izquierdo-Domínguez; Antonio L Valero; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.